{
  "docId": "019de072-4935-7342-8528-4e6eca3fe5c7",
  "docSlug": "31ea92baba83669e6443d115d329d67b",
  "documentTitle": "AstraZeneca | Investor Presentation Deck | 53 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 53,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "customer_journey",
  "function": "frame_situation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a matrix-like structure to map patient segments (NHA naive vs experienced) against disease stages (Hormone sensitive vs Castration resistant).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4935-7342-8528-4e6eca3fe5c7/41",
  "deckHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7",
  "deckJsonHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7.json",
  "deckAnchorHref": "/decks/019de072-4935-7342-8528-4e6eca3fe5c7#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.08,
        "x": 0.91,
        "y": 0.03
      },
      "kind": "callout",
      "text": "ASCO GU 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c3f03fc-1e78-4dd7-a057-48ef670d0708",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.75,
        "x": 0.15,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Treatment pathway matrix",
      "attrs": null,
      "subkind": "customer-journey",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c220da77-3524-4805-b296-af5fda67cb29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: AstraZeneca estimates. Indicative populations. Not to scale 1. Rawla P. World J Oncol. 2019; 10(2):63-89. 2. Mateo, J, et al. New England Journal of Medicine, 2015, 373(18), pp.1697 - 1708.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78db506f-a297-4132-a005-8163a7559108",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "mCRPC therapies are limited; mostly monotherapy, including in first line",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94f4307a-dd4c-46c9-bf87-d543f723db8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Prostate is the second most common cancer in male patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a502f59-a06d-4dc8-97d5-921948110930",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Customer journey map",
      "slug": "customer-journey-map",
      "agent": null,
      "layer": "slide",
      "matchId": "1fe29d10-13f6-4318-885e-ee5c8ea76030",
      "evidence": "diagram/customer-journey: Treatment pathway matrix",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "customer-journey-map",
      "slug": null,
      "matchId": "361a2ef1-fae5-4c25-a6f5-0314910234b6",
      "evidence": "The slide maps the progression of prostate cancer patients through different treatment stages.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}